Related Experiment Video

Updated: May 16, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Gene polymorphism of angiotensin II type 1 and type 2 receptors

Tomohiro Katsuya1, Ryuichi Morishita

  • 1Katsuya Clinic, Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, 2-17-21 Nanamatsu-cho, Amagasaki, Hyogo 660-0052, Japan. tkatsuya@iris.eonet.ne.jp

Current Pharmaceutical Design
|November 27, 2012
PubMed

Insights

Genetic variations in the renin-angiotensin system (RAS) receptors, AGTR1 and AGTR2, are linked to cardiovascular disease risks and medication response. Specific single nucleotide polymorphisms (SNPs) offer potential clinical utility.

Area of Science:

  • Cardiovascular Genetics
  • Pharmacogenomics
  • Molecular Medicine

Background:

  • The renin-angiotensin system (RAS) is crucial in cardiovascular disease (CVD) pathogenesis and drug response.
  • Genetic variations in RAS genes, particularly angiotensinogen and angiotensin-converting enzyme, have been extensively studied.
  • Single nucleotide polymorphisms (SNPs) in angiotensin II receptor genes (AGTR1 and AGTR2) also show associations with CVD.

Purpose of the Study:

  • To review genetic investigations of AGTR1 and AGTR2.
  • To explore the clinical utility of SNPs in these angiotensin II receptor genes.
  • To summarize findings on the association between RAS gene variants and cardiovascular diseases.

Main Methods:

  • Review of previous genetic association studies.
  • Analysis of single nucleotide polymorphisms (SNPs) in AGTR1 and AGTR2 genes.
  • Focus on A1166C polymorphism of AGTR1 and G1675A polymorphism of AGTR2.

Main Results:

  • The AGTR1 A1166C polymorphism (C1166 allele) is associated with increased risk for coronary artery disease, ischemic stroke, heart failure, and end-stage renal disease, but not hypertension.
  • AGTR1 A1166C may modulate the efficacy of RAS inhibitors.
  • The AGTR2 G1675A polymorphism (G1675 allele) is linked to increased risk for left ventricular hypertrophy, renal insufficiency, and altered hemodynamic responses to RAS inhibitors.

Conclusions:

  • SNPs in AGTR1 and AGTR2 are associated with various cardiovascular conditions and influence response to RAS inhibitors.
  • These genetic variants hold potential for clinical utility in personalized medicine.
  • Further research is warranted to fully elucidate the clinical significance of these RAS receptor SNPs.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy09:51

Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy

Published on: March 27, 2017

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...